IDEAYA Biosciences, Inc. (IDYA) has a negative trailing P/E of -24.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 15.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.13%, forward earnings yield 6.39%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -13.4 | 0.00 | -10.12 | 0.00 | - |
| 2018 | -4.6 | -0.02 | -3.26 | 0.00 | - |
| 2019 | -3.6 | 0.17 | 1.51 | 0.00 | - |
| 2020 | -10.0 | 0.32 | 1.75 | 17.71 | - |
| 2021 | -16.7 | -2.19 | 2.76 | 29.83 | - |
| 2022 | -12.8 | -18.10 | 2.15 | 14.79 | - |
| 2023 | -18.1 | -0.48 | 3.30 | 87.52 | - |
| 2024 | -7.6 | -0.11 | 1.98 | 299.88 | - |
| 2025 | -26.9 | 0.43 | 2.99 | 13.99 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.83 | $0.00 | $-11.86M | - |
| 2018 | $-2.41 | $0.00 | $-34.35M | - |
| 2019 | $-1.90 | $0.00 | $-38.44M | - |
| 2020 | $-1.31 | $19.54M | $-32.27M | -165.1% |
| 2021 | $-1.35 | $27.94M | $-47.53M | -170.1% |
| 2022 | $-1.32 | $50.93M | $-54.81M | -107.6% |
| 2023 | $-1.96 | $23.39M | $-112.96M | -483% |
| 2024 | $-3.36 | $7M | $-274.48M | -3921.1% |
| 2025 | $-1.28 | $218.71M | $-113.7M | -52% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.97 | $-4.84 – $-3.00 | $36.33M | $29.82M – $51.85M | 13 |
| 2027 | $-3.41 | $-4.52 – $-0.37 | $120.87M | $21.1M – $183.3M | 11 |
| 2028 | $-2.44 | $-4.01 – $0.80 | $276.68M | $276.68M – $276.68M | 10 |
| 2029 | $-0.65 | $-1.49 – $-0.06 | $567.27M | $170.97M – $1.14B | 4 |
| 2030 | $2.07 | $0.19 – $4.77 | $986.41M | $297.29M – $1.98B | 4 |
